Maduramycin and kifunensine for modulating high mannose glycoforms in antibody-based protein therapeutics

Authors

• Nandita V ishwanathan, Merck Serono SA, SwitzerlandFollow
• Thomas Vuillemin, Merck Serono SA
• Patrick Romann, University of Applied Sciences and Arts Northwestern Switzerland
• Martin Jordan, Merck Serono SA
• Jean-Marc Bielser, Merck Serono SA
• Thomas K. Villiger, University of Applied Sciences and Arts Northwestern Switzerland

Conference Dates

April 27 - May 2, 2025

Abstract

Please click Additional Files below to see the full abstract

Recommended Citation

Nandita V ishwanathan, Thomas Vuillemin, Patrick Romann, Martin Jordan, Jean-Marc Bielser, and Thomas K. Villiger, "Maduramycin and kifunensine for modulating high mannose glycoforms in antibody-based protein therapeutics" in "Cell Culture Engineering XIX", A Khetan, BMS; Marcella Yu, Gilead; Mike Betenbaugh, Johns Hopkins University Eds, ECI Symposium Series, (2025). https://dc.engconfintl.org/cell_culture_engineering_xix/147